{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:18:51Z","timestamp":1790137131978,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Debiopharm International SA"},{"name":"Ascenta Therapeutics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clml.2015.02.020","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T23:03:39Z","timestamp":1425510219000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia\u2014Results of a Phase I Dose-Escalation Study"],"prefix":"10.1016","volume":"15","author":[{"given":"John F.","family":"DiPersio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Brill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Vuagniaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-8824","authenticated-orcid":false,"given":"Elisabeth","family":"Rouits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mel","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.020_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1535-6108(02)00241-6","article-title":"Apoptosis-targeted therapies for cancer","volume":"3","author":"Reed","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.020_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.clml.2015.02.020_bib3","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/onc.2008.302","article-title":"IAP-targeted therapies for cancer","volume":"27","author":"LaCasse","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2015.02.020_bib4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10495-007-0087-3","article-title":"The inhibitors of apoptosis (IAPs) as cancer targets","volume":"12","author":"Hunter","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.clml.2015.02.020_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1586\/14737140.7.9.1255","article-title":"Inhibitor of apoptosis proteins as targets for anticancer therapy","volume":"7","author":"Fulda","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2015.02.020_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrc2889","article-title":"IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer","volume":"10","author":"Gyrd-Hansen","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.02.020_bib7","doi-asserted-by":"crossref","first-page":"24295","DOI":"10.1074\/jbc.C800128200","article-title":"c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation","volume":"283","author":"Varfolomeev","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2015.02.020_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2009.11.021","article-title":"IAP regulation of metastasis","volume":"17","author":"Mehrotra","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.020_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccr.2007.08.029","article-title":"Autocrine TNFalpha signaling renders human cancer cells susceptible to SMAC-mimetic-induced apoptosis","volume":"12","author":"Petersen","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.020_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/ijc.23278","article-title":"Downregulation of XIAP expression in ovarian cancer cells induces cell death in\u00a0vitro and in\u00a0vivo","volume":"122","author":"Shaw","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2015.02.020_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1535-6108(03)00332-5","article-title":"Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity","volume":"5","author":"Schimmer","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.020_bib12","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/sj.leu.2403113","article-title":"Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia","volume":"17","author":"Carter","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.020_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","article-title":"Guidelines on the management of acute myeloid leukaemia in adults","volume":"135","author":"British Committee for Standards in Haematology","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.020_bib14","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment\u00a0outcomes in acute myeloid leukemia (AML) in older patients: the results\u00a0of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib15","first-page":"379","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clml.2015.02.020_bib16","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib17","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2015.02.020_bib18","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib19","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group","volume":"93","author":"Buchner","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib20","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1200\/JCO.2006.10.2731","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older patients","volume":"25","author":"Estey","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.020_bib21","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.1993.11.10.2002","article-title":"Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia","volume":"11","author":"Feldman","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.020_bib22","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","volume":"89","author":"Hann","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2141.2005.05745.x","article-title":"Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients","volume":"131","author":"Russo","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.020_bib24","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","article-title":"Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia","volume":"27","author":"Schimmer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.020_bib25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.020_bib27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2147\/OTT.S33375","article-title":"IAP proteins as targets for drug development in oncology","volume":"9","author":"Dubrez","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2015.02.020_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/1078-0432.CCR-13-0227","article-title":"Molecular pathways: targeting inhibitor of apoptosis proteins in cancer-from molecular mechanism to therapeutic application","volume":"20","author":"Fulda","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.02.020_bib29","doi-asserted-by":"crossref","unstructured":"Hurwitz HI, Smith DC, Pitot HC, et\u00a0al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol Epub 2015 Feb\u00a027.","DOI":"10.1007\/s00280-015-2709-8"},{"key":"10.1016\/j.clml.2015.02.020_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/toxsci\/kfs265","article-title":"Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-alpha pharmacology","volume":"131","author":"Erickson","year":"2013","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.clml.2015.02.020_bib31","doi-asserted-by":"crossref","first-page":"G611","DOI":"10.1152\/ajpgi.00111.2013","article-title":"Degradation of cIAPs contributes to hepatocyte lipoapoptosis","volume":"305","author":"Akazawa","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clml.2015.02.020_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.10232","article-title":"Mucositis in patients with hematologic malignancies: an overview","volume":"92","author":"Niscola","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.020_bib33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/01.CCM.0000266683.64081.02","article-title":"Mechanisms of sepsis-induced cardiac dysfunction","volume":"35","author":"Rudiger","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clml.2015.02.020_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-100-4-483","article-title":"Profound but reversible myocardial depression in patients with septic shock","volume":"100","author":"Parker","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.02.020_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/bja\/aeh171","article-title":"The heart and circulation in severe sepsis","volume":"93","author":"Young","year":"2004","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clml.2015.02.020_bib36","first-page":"392","article-title":"Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans","volume":"34","author":"Wan","year":"1974","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2015.02.020_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia: multicenter, phase III study","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.020_bib38","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1200\/JCO.2011.38.9601","article-title":"Going beyond 7\u00a0+ 3 regimens in the treatment of adult acute myeloid leukemia","volume":"30","author":"Tefferi","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:47Z","timestamp":1761870407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S2152265015000646"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia\u2014Results of a Phase I Dose-Escalation Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}